Sienna Gestion Invests $1.75 Million in Stryker Corporation $SYK

Sienna Gestion acquired a new position in shares of Stryker Corporation (NYSE:SYK) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,963 shares of the medical technology company’s stock, valued at approximately $1,749,000.

A number of other institutional investors have also added to or reduced their stakes in SYK. Brighton Jones LLC lifted its holdings in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares in the last quarter. Schnieders Capital Management LLC. purchased a new stake in Stryker during the 2nd quarter worth about $205,000. Marshall Wace LLP lifted its holdings in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares in the last quarter. Nebula Research & Development LLC purchased a new stake in Stryker during the 2nd quarter worth about $219,000. Finally, HUB Investment Partners LLC purchased a new stake in Stryker during the 2nd quarter worth about $253,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Sanford C. Bernstein set a $410.00 price objective on Stryker in a report on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $465.00 price target on shares of Stryker in a report on Wednesday, March 4th. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Needham & Company LLC lowered their price target on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Finally, Evercore set a $355.00 price target on Stryker in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $395.33.

Stryker Stock Performance

NYSE:SYK opened at $307.86 on Tuesday. The business’s 50-day moving average price is $315.93 and its two-hundred day moving average price is $343.32. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87. The stock has a market cap of $118.02 billion, a P/E ratio of 35.63, a PEG ratio of 1.97 and a beta of 0.78. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.